Avaliação do efeito anticonvulsivante de fitocanabinoides de grau farmacêutico nas crises agudas induzidas pela pilocarpina em ratos wistar
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
The treatment of epilepsy is challenging due to the existence of forms resistant to
pharmacological and surgical treatments, with refractoriness affecting 30% of patients,
resulting in considerable morbidity and mortality. The present study evaluated the protective
(inhibitory) effect of different formulations of pharmaceutical-grade phytocannabinoids in an
oily vehicle and an aqueous formulation in nanoparticles on acute epileptic seizures,
specifically in the form of Status Epilepticus (SE). Seventy adult male Wistar rats, sourced from
the Bioterium of the Center for Reproductive Biology at UFJF, were used, subdivided into
groups, in which the seizures were induced using the pilocarpine model via intraperitoneal
injection. The intraperitoneal injection of the compounds compared the protective effect exerted
by established antiepileptic drugs for the treatment of acute convulsive seizures with
pharmaceutical-grade phytocannabinoids. The protective effect of different pharmaceuticalgrade phytocannabinoid formulations: (isolated Cannabidiol, Cannabidiol+Cannabigerol,
Cannabidiol+Cannabigerol+THC, Cannabinol+Cannabichromene+Cannabigerol, and
Cannabidiol+Cannabigerol+Cannabichromene in aqueous nanoparticles) was compared to
Midazolam, considered a positive control, administered intraperitoneally before the induction
of seizures. The evaluation included the incidence of SE, the latency to the onset of seizures,
and the behavioral severity according to the Racine scale and colinergic simptons.. Among the
phytocannabinoids used in the experiment, the combination of Cannabidiol, Cannabigerol, and
THC demonstrated the most robust protective effect (80%), with a trend similar to Midazolam.
On the other hand, isolated Cannabidiol showed 40% protection in the tested group, while the
formulation in aqueous nanoparticles was the group that performed the worst, with only 30%
protection and the shortest latency to the onset of seizures. The other phytocannabinoids
combinations (Cannabidiol+Cannabigerol and Cannabinol+Cannabichromene Cannabigerol)
showed intermediate protection (50%). The combination of phytocannabinoids, especially the
one that includes THC in its pharmaceutical-grade formulation, can offer a significant
protective effect against acute epileptic seizures, reinforcing the "entourage effect" hypothesis
and indicating therapeutic potential for the management of refractory epilepsies and SE. The
variation in efficacy between different formulations suggests that composition and
bioavailability are crucial factors, and the lower efficacy of the formulation in aqueous
nanoparticles can be explained by a possible inverted "U" dose-response curve, where altered
bioavailability would result in concentrations outside the therapeutic window.
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

